Stromal genes add prognostic information to proliferation and histoclinical markers: A basis for the next generation of breast cancer gene signatures

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Mefford, Dwain ^a   Mefford, Joel ^b  

^a University of California San Francisco ^*

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DECORIN; LAMININ;

ADULT; AGE DISTRIBUTION; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DCN GENE; ESTROGEN RECEPTOR NEGATIVE BREAST CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FBLN1 GENE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LAMA2 GENE; MAJOR CLINICAL STUDY; MARKER GENE; POPULATION RESEARCH; TUMOR GENE; TUMOR GROWTH;

BREAST NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; COHORT STUDIES; FEMALE; HUMANS; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; STROMAL CELLS; TUMOR MARKERS, BIOLOGICAL;

EID: 84862492494     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037646     Document Type: Article

References (58)

1. Weigelt B, Baehner FL, Reis-Filho JS, (2010) The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. The Journal of Pathology 220: 263-280.
2. Weigelt B, Mackay A, A'hern R, Natrajan R, Tan D, et al. (2010) Breast cancer molecular profiling with single sample predictors: a retrospective analysis. The Lancet Oncology.
3. Perou CM, Parker JS, Prat A, Ellis MJ, Bernard PS, (2010) Clinical implementation of the intrinsic subtypes of breast cancer. The Lancet Oncology 11: 718-719.
4. Sørlie T, Borgan E, Myhre S, Vollan HK, Russnes H, et al. (2010) The importance of gene-centring microarray data. The Lancet Oncology 11: 719-720.
5. Colombo PE, Milanezi F, Weigelt B, Reis-Filho J, (2011) Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction. Breast Cancer Research 13: 212.
6. Zhao X, Rødland EA, Sørlie T, Naume B, Langerød A, et al. (2011) Combining Gene Signatures Improves Prediction of Breast Cancer Survival. PloS One 6: e17845.
7. Geyer FC, Rodrigues DN, Weigelt B, Reis-Filho JS, (2012) Molecular Classification of Estrogen Receptor-positive/Luminal Breast Cancers. Advances in Anatomic Pathology 19: 39.
8. Sotiriou C, Pusztai L, (2009) Gene-expression signatures in breast cancer. New England Journal of Medicine 360: 790.
9. Weigelt B, Pusztai L, Ashworth A, Reis-Filho JS, (2011) Challenges translating breast cancer gene signatures into the clinic. Nature Reviews Clinical Oncology doi:10.1038/nrclinonc.2011.125.
10. Ross JS, Hatzis C, Symmans WF, Pusztai L, Hortobagyi GN, (2008) Commercialized multigene predictors of clinical outcome for breast cancer. The Oncologist 13: 477.
11. van't Veer LJ, Bernards R, (2008) Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 452: 564.
12. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, et al. (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. Journal of Clinical Oncology 25: 5287.
13. Edén P, Ritz C, Rose C, Fernö M, Peterson C, (2004) "Good Old" clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. European Journal of Cancer 40: 1837-1841.
14. Dunkler D, Michiels S, Schemper M, (2007) Gene expression profiling: Does it add predictive accuracy to clinical characteristics in cancer prognosis? European Journal of Cancer 43: 745-751.
15. Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, et al. (2011) Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer. Journal of Clinical Oncology doi:10.1200/jco.2010.31.2835.
16. van't Veer L, Dai H, van de Vijver M, He Y, Hart A, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530.
17. Wang Y, Klijn JGM, Zhang Y, Sieuwerts AM, Look MP, et al. (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. The Lancet 365: 671-679.
18. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, et al. (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. JNCI Cancer Spectrum 98: 262.
19. Loi S, Piccart M, Sotiriou C, (2007) The use of gene-expression profiling to better understand the clinical heterogeneity of estrogen receptor positive breast cancers and tamoxifen response. Critical Reviews In Oncology/Hematology 61: 187-194.
20. Haibe-Kains B, Desmedt C, Piette F, Buyse M, Cardoso F, (2008) Comparison of prognostic gene expression signatures for breast cancer. BMC Genomics 9: 394.
21. Drier Y, Domany E, (2011) Do two machine-learning based prognostic signatures for breast cancer capture the same biological processes? PloS One 6: e17795.
22. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, et al. (2008) Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 10: R65.
23. Haibe-Kains B, Desmedt C, Sotiriou C, Bontempi G, (2008) A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all? Bioinformatics 24: 2200.
24. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, et al. (2008) Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clinical Cancer Research 14: 5158.
25. Reyal F, van Vliet MH, Armstrong NJ, Horlings HM, de Visser KE, et al. (2008) A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the Proliferation, Immune response and RNA splicing modules in breast cancer. Breast Cancer Research 10: R93.
26. Martin KJ, Patrick DR, Bissell MJ, Fournier MV, (2008) Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets. PloS One 3: e2994.
27. Fournier MV, Martin KJ, Kenny PA, Xhaja K, Bosch I, et al. (2006) Gene expression signature in organized and growth-arrested mammary acini predicts good outcome in breast cancer. Cancer Research 66: 7095.
28. Goldhirsch A, Wood W, Coates A, Gelber R, Thurlimann B, et al. (2011) Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of Oncology 22: 1736-1747.
29. Cheang MCU, Chia SK, Voduc D, Gao D, Leung S, et al. (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. Journal of the National Cancer Institute 101: 736.
30. Alexe G, Dalgin GS, Scanfeld D, Tamayo P, Mesirov JP, et al. (2007) High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Research 67: 10669.
31. Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C, (2007) An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biology 8: R157.
32. Schmidt M, Böhm D, von Törne C, Steiner E, Puhl A, et al. (2008) The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Research 68: 5405.
33. Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, et al. (2009) T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Research 11: R15.
34. Bergamaschi A, Tagliabue E, Sørlie T, Naume B, Triulzi T, et al. (2008) Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. The Journal of Pathology 214: 357-367.
35. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, et al. (2008) Stromal gene expression predicts clinical outcome in breast cancer. Nature Medicine 14: 518-527.
36. Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, et al. (2009) A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nature Medicine 15: 68-74.
37. Myhre S, Mohammed H, Tramm T, Alsner J, Finak G, et al. (2010) In Silico Ascription of Gene Expression Differences to Tumor and Stromal Cells in a Model to Study Impact on Breast Cancer Outcome. PloS One 5: e14002.
38. West RB, Nuyten DS, Subramanian S, Nielsen TO, Corless CL, et al. (2005) Determination of stromal signatures in breast carcinoma. PLoS Biol 3: e187.
39. West RB, van de Rijn M, (2007) Experimental approaches to the study of cancer-stroma interactions: recent findings suggest a pivotal role for stroma in carcinogenesis. Lab Invest 87: 967-970.
40. Beck AH, Espinosa I, Gilks CB, van de Rijn M, West RB, (2008) The fibromatosis signature defines a robust stromal response in breast carcinoma. Laboratory Investigation 88: 591-601.
41. Bianchini G, Qi Y, Alvarez R, Iwamoto T, Coutant C, et al. (2010) Molecular Anatomy of Breast Cancer Stroma and Its Prognostic Value in Estrogen Receptor-Positive and-Negative Cancers. Journal of Clinical Oncology 28: 4316-4323.
42. Beck AH, Espinosa I, Edris B, Li R, Montgomery K, et al. (2009) The macrophage colony-stimulating factor 1 response signature in breast carcinoma. Clin Cancer Res 15: 778-787.
43. Mefford D, Mefford J, (2010) Enumerating the gene sets in breast cancer, a "direct" alternative to hierarchical clustering. BMC Genomics 11: 482.
44. Miller LD, Smeds J, George J, Vega VB, Vergara L, et al. (2005) An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proceedings of the National Academy of Sciences of the United States of America 102: 13550.
45. Symmans WF, Hatzis C, Sotiriou C, Andre F, Peintinger F, et al. (2010) Genomic index of sensitivity to endocrine therapy for breast cancer. Journal of Clinical Oncology 28: 4111.
46. Dai H, van't Veer L, Lamb J, He YD, Mao M, et al. (2005) A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Research 65: 4059.
47. Desmedt C, Sotiriou C, (2006) Proliferation: the most prominent predictor of clinical outcome in breast cancer. Cell Cycle (Georgetown, Tex) 5: 2198.
48. [www.ncbi.nlm.nih.gov/geo/] Gene Expression Omnibus (GEO).
49. Pawitan Y, Bjöhle J, Amler L, Borg AL, Egyhazi S, et al. (2005) Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Research 7: R953-R964.
50. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, et al. (2006) Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10: 529-541.
51. www.ebi.ac.uk/arrayexpress ArrayExpress.
52. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, et al. (2007) Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clinical Cancer Research 13: 3207.
53. Abba MC, Drake JA, Hawkins KA, Hu Y, Sun H, et al. (2004) Transcriptomic changes in human breast cancer progression as determined by serial analysis of gene expression. Breast Cancer Research 6: R499-513.
54. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, et al. (2004) Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 6: 17-32.
55. Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, et al. (2004) Circulating tumor cells in patients with breast cancer dormancy. Clinical Cancer Research 10: 8152.
56. [http://www.R-project.org] R Project.
57. Ringner M, Fredlund E, Hakkinen J, Borg A, Staaf J, (2011) GOBO: Gene Expression-Based Outcome for Breast Cancer Online. PloS One 6: e17911.
58. Karn T, Metzler D, Ruckhaberle E, Hanker L, Gatje R, et al. (2010) Data driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer. Breast cancer research and treatment 120: 567-579.